OptimizeRx (OPRX)
Connects life-sciences marketers, clinicians, and patients through prescribing, engagement, and consumer-audience tools.
$7.87
After-hours close+0.22 (+2.88%)
At close$7.65(+1.19%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 28 | 20 | 19 | 21 | 32 | 22 | 29 | 26 | 32 | 20 | 21 |
| Cost of revenue | 7 | 11 | 7 | 7 | 8 | 10 | 9 | 11 | 9 | 8 | 6 | 5 |
| Gross profit | 10 | 18 | 12 | 12 | 13 | 22 | 13 | 19 | 18 | 24 | 14 | 16 |
| 13 | 29 | 17 | 15 | 22 | 18 | 15 | 15 | 15 | 15 | 13 | 16 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| 13 | 19 | 16 | 14 | 13 | 17 | 14 | 14 | 14 | 14 | 8 | 9 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 |
| General & administrative | 13 | 19 | 16 | 14 | 13 | 17 | 14 | 14 | 14 | 14 | 4 | 4 |
| Other expenses | 0 | 10 | 1 | 1 | 8 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Operating income | −4 | −11 | −5 | −4 | −9 | 4 | −2 | 3 | 2 | 9 | 0 | 0 |
| 1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | |
| Interest income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
| Other non-operating income | 0 | −3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −12 | −7 | −5 | −10 | 2 | −3 | 2 | 1 | 7 | −1 | −1 |
| Income tax expense | 0 | −8 | 0 | −1 | −1 | 2 | −1 | 0 | 0 | 2 | 0 | 0 |
| Net income from continuing operations | −3 | −4 | −7 | −4 | −9 | 0 | −2 | 2 | 1 | 5 | 0 | −1 |
| Net income | −3 | −4 | −7 | −4 | −9 | 0 | −2 | 2 | 1 | 5 | 0 | −1 |
| EPS, basic | −$0.17 | −$0.23 | −$0.38 | −$0.22 | −$0.50 | −$0.00 | −$0.12 | $0.08 | $0.04 | $0.27 | −$0.03 | −$0.04 |
| EPS, diluted | −$0.17 | −$0.23 | −$0.38 | −$0.22 | −$0.50 | −$0.00 | −$0.12 | $0.08 | $0.04 | $0.26 | −$0.03 | −$0.04 |
| Weighted average shares, basic | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 19 |
| Weighted average shares, diluted | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 19 |
| EBITDA | −3 | −7 | −4 | −2 | −7 | 5 | −1 | 4 | 3 | 10 | 2 | 1 |
| Depreciation & amortization | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBIT | −4 | −8 | −5 | −4 | −8 | 4 | −2 | 3 | 2 | 9 | 1 | 0 |